You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
澤璟製藥(688266.SH):傑克替尼片治療中、高危骨髓纖維化II期臨牀試驗取得成功結果
格隆匯 02-22 17:08

格隆匯2月22日丨澤璟製藥(688266.SH)公佈,近日,公司自主研發產品鹽酸傑克替尼片(以下簡稱“傑克替尼片”)治療中、高危骨髓纖維化的II期臨牀研究取得成功結果。結果顯示,鹽酸傑克替尼片不僅可以顯著縮小骨髓纖維化患者的脾臟體積、減輕患者的體質性症狀,還可以改善貧血,減少輸血依賴,改善患者的生存質量。

傑克替尼片100mgBID的有效率顯著優於同類進口上市藥物蘆可替尼在中國骨髓纖維化患者中的歷史數據,耐受性和安全性良好。該試驗的詳細數據將於2021年在相關臨牀血液學學術大會上適時公佈。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account